Patents by Inventor Arin Ghasparian

Arin Ghasparian has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20230355737
    Abstract: The present invention relates to the epicutaneous vaccination against RSV vaccination with a skin patch device loaded with a particle exposing an RSV-F protein, a variant or a fragment thereof.
    Type: Application
    Filed: September 24, 2021
    Publication date: November 9, 2023
    Inventors: PIERRE-LOUIS HERVE, LUCIE MONDOULET, NATHALIE DONNE, ARMANDO ZUNIGA, ARIN GHASPARIAN
  • Patent number: 11680085
    Abstract: The present invention relates to a cyclic peptide, a conjugate comprising said cyclic peptide and a lipopeptide building block, a bundle of said conjugates, a synthetic virus-like particle comprising at least one bundle of conjugates and pharmaceutical compositions comprising the same. The present invention further relates to said cyclic peptide, said conjugate said bundle of conjugates, said synthetic virus-like particle and said pharmaceutical compositions for use as a medicament, preferably for use in a method for preventing of an infectious disease or reducing the risk of an infectious disease, more preferably for use in a method for preventing or reducing the risk of an infectious disease associated with or caused by a respiratory syncytial virus.
    Type: Grant
    Filed: June 13, 2018
    Date of Patent: June 20, 2023
    Assignees: VIROMETIX AG, UNIVERSITÄT ZÜRICH
    Inventors: Arin Ghasparian, Armando Zuniga, Aniebrys Marrero Nodarse, Oliver Rassek, John A. Robinson, Kerstin Möhle
  • Publication number: 20220054619
    Abstract: The present invention relates to a lipopeptide building block consisting of (i) a peptide moiety comprising a coiled coil peptide chain segment, wherein said coiled coil peptide chain segment comprises 3 to 8 repeat units, and wherein said repeat unit consists of the sequence IEKKIE-XO (SEQ ID NO:58), wherein X0 represents an amino acid, and wherein preferably said repeat unit consists of the sequence selected from IEKKIEG (SEQ ID NO:59), IEKKIEA (SEQ ID NO:12) or IEKKIES (SEQ ID NO:13), and wherein further preferably said repeat unit consists of the sequence IEKKIES (SEQ ID NO:13); (ii) a lipid moiety comprising, preferably consisting of, the formula LM-I wherein R1 and R2 are independently C11-15alkyl, wherein preferably R1 and R2 are independently —C11H23, —C13H27 or —C15H31, and wherein further preferably R1 and R2 are —C15H31; and wherein R3 is hydrogen or —C(O)C11-15alkyl, and wherein preferably R3 is H or —C(O)C15H31; and wherein said lipid moiety is linked to said peptide moiety, wherein the wavy line
    Type: Application
    Filed: December 19, 2019
    Publication date: February 24, 2022
    Inventors: Arin GHASPARIAN, John A. ROBINSON
  • Publication number: 20210101941
    Abstract: The present invention relates to a cyclic peptide, a conjugate comprising said cyclic peptide and a lipopeptide building block, a bundle of said conjugates, a synthetic virus-like particle comprising at least one bundle of conjugates and pharmaceutical compositions comprising the same. The present invention further relates to said cyclic peptide, said conjugate said bundle of conjugates, said synthetic virus-like particle and said pharmaceutical compositions for use as a medicament, preferably for use in a method for preventing of an infectious disease or reducing the risk of an infectious disease, more preferably for use in a method for preventing or reducing the risk of an infectious disease associated with or caused by a respiratory syncytial virus.
    Type: Application
    Filed: June 13, 2018
    Publication date: April 8, 2021
    Inventors: Arin GHASPARIAN, Armando ZUNIGA, Aniebrys MARRERO NODARSE, Oliver RASSEK, John A. ROBINSON, Kerstin MÖHLE
  • Publication number: 20180256698
    Abstract: The invention relates to lipopeptides consisting of a peptide chain comprising a parallel coiled-coil domain, a proline-rich peptide antigen, and a lipid moiety, all covalently linked, which aggregate to synthetic virus-like particles. Proline-rich peptide antigens considered contain negatively and positively charged amino acid, and at least 15% of the amino acids are proline. Such synthetic virus-like particles carrying proline-rich antigens derived from pneumococcal proteins are useful as vaccines against infectious diseases caused by Gram-positive bacteria such as Streptococcus pneumoniae.
    Type: Application
    Filed: February 28, 2018
    Publication date: September 13, 2018
    Inventors: Arin Ghasparian, Armando Zuniga, Nina Geib, Marco Tamborrini, Maja Jud, Gerd Pluschke, Aniebrys Marrero Nodarse, John Anthony Robinson
  • Patent number: 9943583
    Abstract: The invention relates to lipopeptides consisting of a peptide chain comprising a parallel coiled-coil domain, a proline-rich peptide antigen, and a lipid moiety, all covalently linked, which aggregate to synthetic virus-like particles. Proline-rich peptide antigens considered contain negatively and positively charged amino acid, and at least 15% of the amino acids are proline. Such synthetic virus-like particles carrying proline-rich antigens derived from pneumococcal proteins are useful as vaccines against infectious diseases caused by Gram-positive bacteria such as Streptococcus pneumoniae.
    Type: Grant
    Filed: December 2, 2014
    Date of Patent: April 17, 2018
    Assignees: UNIVERSITÄT ZÜRICH, SWISS TROPICAL AND PUBLIC HEALTH INSTITUTE, VIROMETIX AG
    Inventors: Arin Ghasparian, Armando Zuniga, Nina Geib, Marco Tamborini, Maja Jud, Gerd Pluschke, Aniebrys Marrero Nodarse, John Anthony Robinson
  • Publication number: 20160324947
    Abstract: The invention relates to lipopeptides consisting of a peptide chain comprising a parallel coiled-coil domain, a proline-rich peptide antigen, and a lipid moiety, all covalently linked, which aggregate to synthetic virus-like particles. Proline-rich peptide antigens considered contain negatively and positively charged amino acid, and at least 15% of the amino acids are proline. Such synthetic virus-like particles carrying proline-rich antigens derived from pneumococcal proteins are useful as vaccines against infectious diseases caused by Gram-positive bacteria such as Streptococcus pneumoniae.
    Type: Application
    Filed: December 2, 2014
    Publication date: November 10, 2016
    Applicant: UNIVERSITÄT ZÜRICH
    Inventors: Arin Ghasparian, Armando Zuniga, Nina Geib, Marco Tamborini, Maja Jud, Gerd Pluschke, Aniebrys Marrero Nodarse, John Anthony Robinson
  • Patent number: 8450284
    Abstract: The invention relates to lipopeptide building blocks consisting of a peptide chain comprising a coiled-coil domain, linked covalently to a lipid moiety comprising long alkyl or alkenyl chains, and optionally linked to an antigen; and to helical lipopeptide bundles and synthetic virus-like particles formed by aggregation. The nanometer size and shape of these bundles and particles, their stability under aqueous physiological conditions, their chemical composition, the possibility to incorporate B- and T-cell epitopes, and their production by chemical synthesis, make them highly suitable as vaccine delivery vehicles.
    Type: Grant
    Filed: December 6, 2007
    Date of Patent: May 28, 2013
    Assignee: Universitaet Zuerich
    Inventors: Francesca Boato, Anabelle Freund, Arin Ghasparian, Kerstin Möhle, John A. Robinson, Richard M. Thomas
  • Publication number: 20100015173
    Abstract: The invention relates to lipopeptide building blocks consisting of a peptide chain comprising a coiled-coil domain, linked covalently to a lipid moiety comprising long alkyl or alkenyl chains, and optionally linked to an antigen; and to helical lipopeptide bundles and synthetic virus-like particles formed by aggregation. The nanometer size and shape of these bundles and particles, their stability under aqueous physiological conditions, their chemical composition, the possibility to incorporate B- and T-cell epitopes, and their production by chemical synthesis, make them highly suitable as vaccine delivery vehicles.
    Type: Application
    Filed: December 6, 2007
    Publication date: January 21, 2010
    Applicant: UNIVERSITÄT ZÓRICH PROREKTORAT FORSCHUNG
    Inventors: Francesca Boato, Annabelle Freund, Arin Ghasparian, Kerstin Moehle, John A. Robinson, Richard M. Thomas